Analyst Reco. Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
1.43 ^USD	-8.92%		+1.42%	-86.84%

08/05	Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	MT
08/05	Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating	07/05	MT
Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	17/04	MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	16/04	MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk	16/04	MT
RBC Raises Price Target on Marinus Pharmaceuticals to $24 From $21, Keeps Outperform Rating	03/01	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $25 From $32, Maintains Buy Rating	08/11	MT
RBC Lifts Price Target on Marinus Pharmaceuticals to $21 From $20, Keeps Outperform Rating, Speculative Risk Qualifier	20/23/20	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $32 From $42, Maintains Buy Rating	11/23/11	MT
Ladenburg Thalmann Adjusts Price Target on Marinus Pharmaceuticals to $13 From $17, Maintains Buy Rating	11/23/11	MT
Oppenheimer Downgrades Marinus Pharmaceuticals to Perform From Outperform, Adjusts Price Target to $9 From $14	11/23/11	MT
Baird Adjusts Price Target on Marinus Pharmaceuticals to $20 From $24, Keeps Outperform Rating	11/23/11	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $20 From $21, Keeps Outperform Rating, Speculative Risk Qualifier	11/23/11	MT
Truist Adjusts Price Target on Marinus Pharmaceuticals to $42 From $50, Keeps Buy Rating	12/23/12	MT
RBC Lowers Price Target on Marinus Pharmaceuticals to $21 From $22, Maintains Outperform, Speculative Risk	12/23/12	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $14 From $12, Maintains Outperform Rating	25/23/25	MT
JMP Securities Adjusts Price Target on Marinus Pharmaceuticals to $18 From $19, Maintains Market Outperform Rating	08/23/08	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $22 From $23, Maintains Outperform, Speculative Risk	08/23/08	MT
SVB Securities Adjusts Price Target on Marinus Pharmaceuticals to $23 From $27, Maintains Outperform Rating	23/23/23	MT
RBC Initiates Marinus Pharmaceuticals at Outperform, Speculative Risk, Sets Price Target at $23	20/23/20	MT
Baird Lowers Price Target on Marinus Pharmaceuticals to $24 From $32, Maintains Outperform Rating	09/22/09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Analyst Reco.

Filters